976 related articles for article (PubMed ID: 9349573)
1. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma.
Alam MS; Takeuchi R; Kasagi K; Misaki T; Miyamoto S; Iida Y; Hidaka A; Konishi J
Thyroid; 1997 Oct; 7(5):705-12. PubMed ID: 9349573
[TBL] [Abstract][Full Text] [Related]
2. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases.
Unal S; Menda Y; Adalet I; Boztepe H; Ozbey N; Alagöl F; Cantez S
J Nucl Med; 1998 Nov; 39(11):1897-902. PubMed ID: 9829579
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of technetium-99m hydroxymethylene diphosphonate scans in localizing bone metastases of differentiated thyroid carcinoma.
Tenenbaum F; Schlumberger M; Bonnin F; Lumbroso J; Aubert B; Benali H; Parmentier C
Eur J Nucl Med; 1993 Dec; 20(12):1168-74. PubMed ID: 8299652
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 99Tcm-tetrofosmin with 201Tl and 131I in the detection of differentiated thyroid cancer metastases.
Nishiyama Y; Yamamoto Y; Ono Y; Takahashi K; Nakano S; Satoh K; Ohkawa M; Tanabe M
Nucl Med Commun; 2000 Oct; 21(10):917-23. PubMed ID: 11130332
[TBL] [Abstract][Full Text] [Related]
5. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma.
Nakada K; Katoh C; Kanegae K; Tsukamoto E; Shiga T; Mochizuki T; Itoh K; Tamaki N
J Nucl Med; 1998 May; 39(5):807-10. PubMed ID: 9591580
[TBL] [Abstract][Full Text] [Related]
6. Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer.
Carril JM; Quirce R; Serrano J; Banzo I; Jiménez-Bonilla JF; Tabuenca O; Barquín RG
J Nucl Med; 1997 May; 38(5):686-92. PubMed ID: 9170428
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.
Fujie S; Okumura Y; Sato S; Akaki S; Katsui K; Himei K; Takemoto M; Kanazawa S
Acta Med Okayama; 2005 Jun; 59(3):99-107. PubMed ID: 16049563
[TBL] [Abstract][Full Text] [Related]
8. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
[TBL] [Abstract][Full Text] [Related]
10. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
12. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
13. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
14. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
15. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
[TBL] [Abstract][Full Text] [Related]
17. Potential of (99m)Tc-MIBI for detecting bone marrow metastases.
Wakasugi S; Noguti A; Katuda T; Hashizume T; Hasegawa Y
J Nucl Med; 2002 May; 43(5):596-602. PubMed ID: 11994520
[TBL] [Abstract][Full Text] [Related]
18. Routine 201Tl scintigraphy in the follow-up of patients with differentiated thyroid carcinoma: diagnostic accuracy and clinical impact.
Hsu CC; Chen YW; Huang YF; Chuang YW
Nucl Med Commun; 2007 Sep; 28(9):681-7. PubMed ID: 17667746
[TBL] [Abstract][Full Text] [Related]
19. [Clinical usefulness of 201Tl-chloride scintigraphy for the evaluation of metastatic bone lesions].
Fukui A; Kawamura M; Kataoka M; Fujii T; Yamamoto K; Yoshioka S; Ikezoe J
Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Jan; 58(1):25-33. PubMed ID: 9493430
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 201Tl, 99Tcm-MIBI and 131I imaging in the follow-up of patients with well-differentiated thyroid carcinoma.
Uğur O; Kostakoğlu L; Caner B; Güler N; Gülaldi NC; Ozmen M; Uysal U; Elahi N; Erbengi G; Bejdik C
Nucl Med Commun; 1996 May; 17(5):373-7. PubMed ID: 8736512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]